GIORDANO, GUIDO
 Distribuzione geografica
Continente #
EU - Europa 718
NA - Nord America 379
AS - Asia 85
SA - Sud America 3
Totale 1.185
Nazione #
IE - Irlanda 377
US - Stati Uniti d'America 374
SE - Svezia 159
IT - Italia 88
CN - Cina 38
SG - Singapore 34
UA - Ucraina 28
DE - Germania 20
FI - Finlandia 13
CZ - Repubblica Ceca 9
FR - Francia 7
CA - Canada 5
GB - Regno Unito 4
IN - India 4
CL - Cile 3
AE - Emirati Arabi Uniti 2
BD - Bangladesh 2
ID - Indonesia 2
JP - Giappone 2
NL - Olanda 2
NO - Norvegia 2
PL - Polonia 2
RO - Romania 2
RU - Federazione Russa 2
BE - Belgio 1
DK - Danimarca 1
ES - Italia 1
MY - Malesia 1
Totale 1.185
Città #
Dublin 376
Nyköping 125
Ashburn 52
New York 36
Chandler 34
Princeton 30
Jacksonville 27
Singapore 22
Wilmington 16
Helsinki 13
Seattle 13
Munich 10
Brno 9
Bari 8
Grosseto 8
Los Angeles 6
Rome 6
Shanghai 6
Des Moines 5
Milan 5
Washington 5
Chengdu 4
Noicattaro 4
Pune 4
Borås 3
Foggia 3
Marostica 3
Potenza 3
San Mateo 3
Toronto 3
Ajman 2
Bitonto 2
Boardman 2
Chieti 2
Ferrara 2
Guangzhou 2
Hanover 2
Jakarta 2
Jiaxing 2
Lipetsk 2
London 2
Lyon 2
Minneapolis 2
Monopoli 2
Noci 2
Norwalk 2
Paris 2
Redmond 2
Salerno 2
Santarcangelo di Romagna 2
Stevenage 2
Toyohashi 2
Acquaviva delle Fonti 1
Adelfia 1
Augusta 1
Beaufays 1
Beijing 1
Bucharest 1
Centralia 1
Chestnut Hill 1
Clearwater 1
Florence 1
Forlimpopoli 1
Gdansk 1
Heze 1
Iasi 1
Jinhua 1
Ladispoli 1
Naples 1
Parma 1
Petaling Jaya 1
Qingdao 1
Quanzhou 1
Rockville 1
Rui'an 1
San Giorgio Del Sannio 1
San Severo 1
Sopot 1
Tappahannock 1
Turin 1
Verona 1
Wuxi 1
Totale 916
Nome #
Obstructive Sleep Apnea Worsens Progression-Free and Overall Survival in Human Metastatic Colorectal Carcinoma 47
NAB-paclitaxel and gemcitabine in metastatic pancreatic ductal adenocarcinoma (PDAC): From clinical trials to clinical practice 43
Differential and divergent activity of insulin-like growth factor binding protein 6 in platinum-sensitive versus platinum-resistant high-grade serous ovarian carcinoma cell lines 41
Crosstalk between the tumor microenvironment and immune system in pancreatic ductal adenocarcinoma: Potential targets for new therapeutic approaches 40
Cancer drug related cardiotoxicity during breast cancer treatment 39
Complete response to capecitabine in a frail, elderly patient with metastatic colorectal cancer: A case report 39
Eribulin Treatment in Patients with Liver Metastatic Breast Cancer: Eight Italian Case Reports 39
Cancer-Associated Immune Resistance and Evasion of Immune Surveillance in Colorectal Cancer 38
Germinal BRCA1-2 pathogenic variants (gBRCA1-2pv) and pancreatic cancer: epidemiology of an Italian patient cohort 37
CROC-Mutated rhabdoid colorectal carcinoma showing in intracellular spaces lamellipodia and cellular projectionts revealed by electron microscopy 37
Targeting Angiogenesis and Tumor Microenvironment in Metastatic Colorectal Cancer: Role of Aflibercept 37
Cancer-related CD15/FUT4 overexpression decreases benefit to agents targeting EGFR or VEGF acting as a novel RAF-MEK-ERK kinase downstream regulator in metastatic colorectal cancer 36
Centrosome linker–induced tetraploid segregation errors link rhabdoid phenotypes and lethal colorectal cancers 36
JAK/Stat5-mediated subtype-specific lymphocyte antigen 6 complex, locus G6D (LY6G6D) expression drives mismatch repair proficient colorectal cancer 36
Eribulin for metastatic breast cancer (MBC) treatment: A retrospective, multicenter study based in Campania, south Italy (Eri-001 trial) 34
Colonic Ewing Sarcoma/PNET associated with liver metastases: A systematic review and case report 33
Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): A randomized phase II trial of FOLFOX plus cetuximab versus FOLFOX 33
Evidence‐based second‐line treatment in ras wild‐type/mutated metastatic colorectal cancer in the precision medicine era 33
Immune escape mechanisms in colorectal cancer pathogenesis and liver metastasis 32
Eribulin plus trastuzumab in pretreated HER2-positive advanced breast cancer patients: safety and efficacy. An Italian experience. 32
Morphology and molecular features of rare colorectal carcinoma histotypes 31
Aberrant BLM cytoplasmic expressionassociates with DNA damage stress and hypersensitivity to DNA-damaging agents in colorectal cancer 30
Emerging insight into MAPK inhibitors and immunotherapy in colorectal cancer 30
Urothelial bladder carcinoma metastasizing to the eye: A systematic review and case report 30
TRAP1 regulates the response of colorectal cancer cells to hypoxia and inhibits ribosome biogenesis under conditions of oxygen deprivation 30
Metastatic melanoma: An unusual presentation 29
Dose intensity and efficacy of the combination of everolimus and exemestane (EVE/EXE) in a real-world population of hormone receptor-positive (ER+/PgR+), HER2-negative advanced breast cancer (ABC) patients: a multicenter Italian experience 29
Eribulin in male patients with breast cancer: The first report of clinical outcomes 28
Pancreatic Enzyme Replacement and Nutritional Support With nab-Paclitaxel-based First-Line Chemotherapy Regimens in Metastatic Pancreatic Cancer 24
Role of Etiology in Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Counterfactual Event-Based Mediation Analysis 23
Nano albumin bound-paclitaxel in pancreatic cancer: Current evidences and future directions 23
Immune resistance and egfr antagonists in colorectal cancer 23
The classification of neuroendocrine neoplasms of the lung and digestive system according to WHO, 5th edition: similarities, differences, challenges, and unmet needs 19
Real-world comparative effectiveness of nab-paclitaxel plus gemcitabine versus FOLFIRINOX in advanced pancreatic cancer: a systematic review 19
Primary versus secondary antiemetic prophylaxis with NK1 receptor antagonists in patients affected by gastrointestinal malignancies and treated with a doublet or triplet combination regimen including oxaliplatin and/or irinotecan plus fluoropyrimidines: A propensity score matched analysis 19
Recurrent Glioblastoma Treatment: State of the Art and Future Perspectives in the Precision Medicine Era 18
Solitary metastasis from renal cell carcinoma to the choroid plexus: A case illustration and review of the literature 17
What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review (Part 6): Correlation of PD-L1 Expression with the Status of Mismatch Repair System, BRCA, PTEN, and Other Genes 17
What do we have to know about pd-l1 expression in prostate cancer? A systematic literature review. part 5: Epigenetic regulation of pd-l1 15
What do we have to know about pd-l1 expression in prostate cancer? A systematic literature review. part 1: Focus on immunohistochemical results with discussion of pre-analytical and interpretation variables 15
Bcl-10, trypsin and synaptophysin helps recognize acinar cell and mixed acinar neuroendocrine cell carcinoma of the pancreas on both preoperative cytological samples and needle biopsy specimens 15
Lymphocyte antigen 6G6D-mediated modulation through p38α MAPK and DNA methylation in colorectal cancer 15
Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic variants (gBRCA1-2pv): a multicenter survey 13
Single-cell proteo-genomic reveals a comprehensive map of centrosome-associated spliceosome components 12
What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 3: PD-L1, Intracellular Signaling Pathways and Tumor Microenvironment 12
Clinical activity and tolerability of FOLFIRI and cetuximab in elderly patients with metastatic colorectal cancer in the CAPRI-GOIM first-line trial 12
What do we have to know about pd-l1 expression in prostate cancer? A systematic literature review. part 2: Clinic–pathologic correlations 11
What do we have to know about PD-L1 expression in prostate cancer? A systematic literature review. part 4: Experimental treatments in pre-clinical studies (cell lines and mouse models) 11
Centrosome Dynamics and Its Role in Inflammatory Response and Metastatic Process 10
Activity and Safety of NAB-FOLFIRI and NAB-FOLFOX as First-Line Treatment for metastatic Pancreatic Cancer (NabucCO Study) 10
The role of nanoliposomal irinotecan plus fluorouracil/leucovorin in the continuum of care of patients with metastatic pancreatic ductal adenocarcinoma 9
Solitary fibrous tumor/hemangiopericytoma of the cervical spine: A systematic review of the literature with an illustrative case 8
Wnt (canonical and non canonical) pathways in breast carcinoma with extensive vascular invasion and inflammatory breast carcinoma 8
Loss of Primary Cilia Potentiates BRAF/MAPK Pathway Activation in Rhabdoid Colorectal Carcinoma: A Series of 21 Cases Showing Ciliary Rootlet CoiledCoil (CROCC) Alterations 6
Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRCA1-2pv) 6
Propensity for Early Metastatic Spread in Breast Cancer: Role of Tumor Vascularization Features and Tumor Immune Infiltrate 5
Molecular and Clinical Insights in Malignant Brenner Tumor of the Testis With Liver Metastases:A Case Report 3
Totale 1.377
Categoria #
all - tutte 14.977
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 14.977


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021161 0 0 0 0 0 0 35 65 27 33 0 1
2021/2022140 3 0 1 1 10 2 6 15 21 39 2 40
2022/2023745 74 23 44 7 32 50 7 46 390 8 48 16
2023/2024269 27 23 25 19 24 77 13 21 2 3 2 33
2024/202562 44 18 0 0 0 0 0 0 0 0 0 0
Totale 1.377